Nyrada (ASX:NYR) submitted its phase IA first-in-healthy human volunteer clinical trial regulatory package of drug candidate NYR-BI03 for Human Research Ethics Committee review, according to a Tuesday filing with the Australian bourse.
The biotechnology company is developing NYR-BI03 for the potential treatment of stroke and traumatic brain injury, the filing said.
The review, scheduled for January 2025, will allow for the start of volunteer recruitment for the trial, according to the filing.
Shares rose past 2% in afternoon trade Tuesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。